(b)(4).The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot.Based on the information reviewed, the reported patient effect of hemorrhage (difficulty achieving hemostasis) was likely a result of procedural conditions as the steerable guide catheter (sgc) is inserted into the anatomy through an incision in the right groin and femoral vein; the reported anemia (drop in hemoglobin) was likely a secondary effect of the hemorrhage.The reported additional therapy/non-surgical treatment was a result of case specific circumstances, as a femstop was applied and hemostasis was achieved.The reported patient effect of bleeding/hemorrhage, as listed in the mitraclip system instructions for use is a known possible complication associated with mitraclip procedures.There is no indication of a product quality issue with respect to manufacture, design or labeling.
|
This report is submitted for venous access site bleeding post procedure, requiring intervention.It was reported that on (b)(6) 2016, two mitraclips were successfully implanted, reducing the functional mitral regurgitation from grade 3+ to grade 1+.Post procedure, bleeding was noted at the femoral vein access site.There was difficulty achieving hemostasis and a drop in hemoglobin was noted.A femstop was applied and hemostasis was achieved.The event resolved without sequela.Reportedly, the patient is on chronic anticoagulation therapy.Per study physician, the event was not serious.There was no additional information provided.
|